Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Contact information



Primary contact

Mr Hisham Mehanna


Contact details

University Hospitals Coventry and Warwickshire NHS Trust
Clifford Bridge Road
United Kingdom
+44 (0)2476 965 606

Additional identifiers

EudraCT number number


Protocol/serial number

HTA 06/302/129; PET-NECK V1.0 5Feb07

Study information

Scientific title

A multicentre randomised phase III trial comparing Positron Emission Tomography - computed tomography guided watch and wait policy versus planned NECK dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer



Study hypothesis

Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer worldwide with approximately 500,000 new cases/year. It poses a significant therapeutic problem as it has a high mortality and morbidity and survival rates have not considerably improved over the past two decades despite newer aggressive surgical and chemoradiotherapy (CRT) regimens.

CRT is the preferred first line of treatment for several types of HNSCC. For patients with large metastasis to the neck nodes, evidence for management is sparse. Current standard care is neck dissection either before/after CRT. There is debate regarding whether a neck dissection is needed or whether CRT alone is sufficient. Controversy continues mainly due to poor quality and contradictory evidence from prospective and retrospective case series for both management strategies. Furthermore the advent of newer, more accurate functional modalities for the detection of persistent disease, e.g., Positron Emission Tomography - Computed Tomography (PET-CT) scanning have further strengthened this debate.

To test the hypotheses that a PET-CT guided watch and wait policy (experimental arm) is non-inferior to the current practice of planned neck dissection (control arm) when comparing overall and disease-specific survival in the management of advanced (N2 or N3) nodal metastasis in patients treated with CRT for their HNSCC primary. Recurrence, quality of life and cost effectiveness will be assessed as secondary outcomes.

More details can be found at:
Protocol can be found at:

Ethics approval

Oxford Research Ethics Committee A, 09/05/2007, ref: 07/Q1604/35

Study design

Two-arm multi-centre randomised trial. Randomisation 1:1 with stratification (centre, chemotherapy schedule, N stage, T stage).

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Head and neck squamous cell carcinoma (HNSCC)


CRT regimens:
All patients must receive concomitant CRT to be included in the trial. For each patient, the participating centre must specify the schedule that they will use. This regimen must be:
1. A CRT schedule that the centre uses in their normal, peer-reviewed practice
2. The CRT schedule selected must be present in the list of approved trial schedules
The recommended standard radiotherapy schedule for the trial is radiotherapy doses of 65 to 70 Gy in 30 to 35 daily fractions of 2 Gy or more with at least two doses of concomitant three/four weekly intravenous cisplatin 75 to 100 mg/m^2 or carboplatin (4.5 to 5 AUC).

Control arm: planned pre-CRT neck dissections - neck dissections must be performed within two to four weeks of randomisation. The recommended surgical procedure is a modified radical neck dissection This involves removal of lymphatic structures in levels I-V, with preservation of one or more of the following: spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle.
Experimental arm: PET-CT scan

Both groups will be followed up for two years.

Intervention type



Phase III

Drug names

Primary outcome measures

1. Overall survival, measured at at two years
2. Health economics (Quality Adjusted Life Years [QALYs]), measured at at two years

Secondary outcome measures

1. Disease-specific survival, measured at pre-treatment and 3, 6, 12 and 24 months post randomisation
2. Recurrence in the neck, measured at pre-treatment and 3, 6, 12 and 24 months post randomisation
3. Quality of life, measured at pre-treatment and 3, 6, 12 and 24 months post randomisation
4. Complication rates, measured at pre-treatment and 3, 6, 12 and 24 months post randomisation
5. Accuracy of PET-CT scanning for assessing the primary tumour

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Histological diagnosis of oropharyngeal, laryngeal, oral, hypopharyngeal or occult HNSCC
2. Clinical and CT/Magnetic Resonance Imaging (MRI) evidence of nodal metastases staged N2 (a, b or c) or N3
3. Indication to receive curative radical concurrent CRT for primary
4. Fitness for neck dissection surgery

Participant type


Age group




Target number of participants


Participant exclusion criteria

Current exclusion criteria as of 28/01/2011:
1. Patients undergoing resection for their primary tumour, e.g., resection of tonsil or base of tongue with flap reconstruction (diagnostic tonsillectomy not considered an exclusion criteria)
2. Patients with N1 nodal metastasis
3. Patients receiving neo-adjuvant chemoradiotherapy with no concomitant chemotherapy
4. Patients receiving adjuvant chemotherapy
5. Patients undergoing chemo +/- radiotherapy for palliative purposes
6. Patient undergoing radiotherapy alone (not optimal treatment for neck node disease)
7. Distant metastases to chest, liver, bones or other sites
8. Unfit for surgery or chemoradiotherapy
9. Previous treatment for head and neck squamous cell carcinoma
10. Patients have had another cancer diagnosis in the last five years (except basal cell carcinoma or carcinoma of the cervix in situ).
11. Pregnant patients
12. Patients under 18 years of age

Previous exclusion criteria:
10. Patients with occult nodal metastasis, i.e., large nodal metastasis but no proven primary site on clinical assessment

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

University Hospitals Coventry and Warwickshire NHS Trust
United Kingdom

Sponsor information


University Hospitals Coventry and Warwickshire NHS Trust (UK)

Sponsor details

University of Warwick
Clifford Bridge Road
United Kingdom
+44 (0)2476 964 000

Sponsor type




Funder type


Funder name

Health Technology Assessment Programme

Alternative name(s)

NIHR Health Technology Assessment Programme, HTA

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

2016 results in:

Publication citations

Additional files

Editorial Notes

05/05/2016: Publication reference added. 04/02/2011: The overall trial end date for this trial was changed from 31/03/2013 to 31/03/2015.